RSV Vaccines from Pfizer and GSK Gain CDC Advisory Committee's Favor for Older Adults
Portfolio Pulse from Vandana Singh
The CDC's Advisory Committee on Immunization Practices has voted in favor of recommending Pfizer and GSK's RSV vaccines for older adults aged 60 and above. The FDA has approved both vaccines, but the panel advises patients to consult their doctors before taking the shots. Both companies expect to supply the vaccines ahead of the RSV season later this year.
June 22, 2023 | 12:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK's RSV vaccine, Arexvy, gains CDC Advisory Committee's recommendation for older adults aged 60 and above, potentially increasing demand for the vaccine.
The CDC Advisory Committee's recommendation for GSK's RSV vaccine, Arexvy, for older adults aged 60 and above is likely to increase demand for the vaccine. This could lead to higher revenues for GSK and a positive impact on its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Pfizer's RSV vaccine, Abrysvo, gains CDC Advisory Committee's recommendation for older adults aged 60 and above, potentially increasing demand for the vaccine.
The CDC Advisory Committee's recommendation for Pfizer's RSV vaccine, Abrysvo, for older adults aged 60 and above is likely to increase demand for the vaccine. This could lead to higher revenues for Pfizer and a positive impact on its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50